Hayashi Takaharu, Asano Yoshihiro, Shintani Yasunori, Aoyama Hiroshi, Kioka Hidetaka, Tsukamoto Osamu, Hikita Masahide, Shinzawa-Itoh Kyoko, Takafuji Kazuaki, Higo Shuichiro, Kato Hisakazu, Yamazaki Satoru, Matsuoka Ken, Nakano Atsushi, Asanuma Hiroshi, Asakura Masanori, Minamino Tetsuo, Goto Yu-ichi, Ogura Takashi, Kitakaze Masafumi, Komuro Issei, Sakata Yasushi, Tsukihara Tomitake, Yoshikawa Shinya, Takashima Seiji
Departments of Medical Biochemistry and Cardiovascular Medicine.
Departments of Medical Biochemistry and Cardiovascular Medicine,
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1553-8. doi: 10.1073/pnas.1419767112. Epub 2015 Jan 20.
Cytochrome c oxidase (CcO) is the only enzyme that uses oxygen to produce a proton gradient for ATP production during mitochondrial oxidative phosphorylation. Although CcO activity increases in response to hypoxia, the underlying regulatory mechanism remains elusive. By screening for hypoxia-inducible genes in cardiomyocytes, we identified hypoxia inducible domain family, member 1A (Higd1a) as a positive regulator of CcO. Recombinant Higd1a directly integrated into highly purified CcO and increased its activity. Resonance Raman analysis revealed that Higd1a caused structural changes around heme a, the active center that drives the proton pump. Using a mitochondria-targeted ATP biosensor, we showed that knockdown of endogenous Higd1a reduced oxygen consumption and subsequent mitochondrial ATP synthesis, leading to increased cell death in response to hypoxia; all of these phenotypes were rescued by exogenous Higd1a. These results suggest that Higd1a is a previously unidentified regulatory component of CcO, and represents a therapeutic target for diseases associated with reduced CcO activity.
细胞色素c氧化酶(CcO)是线粒体氧化磷酸化过程中唯一利用氧气产生质子梯度以合成ATP的酶。尽管CcO活性会因缺氧而增加,但其潜在的调控机制仍不清楚。通过在心肌细胞中筛选缺氧诱导基因,我们鉴定出缺氧诱导结构域家族成员1A(Higd1a)是CcO的正向调节因子。重组Higd1a直接整合到高度纯化的CcO中并增加其活性。共振拉曼分析表明,Higd1a引起了血红素a周围的结构变化,血红素a是驱动质子泵的活性中心。使用线粒体靶向的ATP生物传感器,我们发现敲低内源性Higd1a会降低氧气消耗及随后的线粒体ATP合成,导致细胞在缺氧时死亡增加;所有这些表型都可通过外源性Higd1a得到挽救。这些结果表明,Higd1a是CcO之前未被识别的调控成分,并且是与CcO活性降低相关疾病的治疗靶点。